iRadimed Corporation $IRMD Shares Purchased by SG Americas Securities LLC

Key Points

• SG Americas Securities boosted its stake in iRadimed by 88.6% in Q4 to 70,391 shares (about $6.85M), and institutional investors now own roughly 92.34% of the company.
• iRadimed beat Q4 estimates with EPS of $0.54 vs. $0.49 and revenue of $22.69M, provided FY2026 EPS guidance of 2.060–2.210, and raised its quarterly dividend to $0.20 (annualized $0.80, 0.8% yield).
• Sell-side analysts give iRadimed a consensus rating of “Moderate Buy” with a consensus target price of $120 (three Buys, one Hold).

SG Americas Securities LLC boosted its position in shares of iRadimed Corporation (NASDAQ:IRMD - Free Report) by 88.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 70,391 shares of the medical equipment provider's stock after buying an additional 33,072 shares during the quarter. SG Americas Securities LLC owned approximately 0.55% of iRadimed worth $6,848,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IRMD. Johnson Investment Counsel Inc. raised its position in shares of iRadimed by 0.7% in the third quarter. Johnson Investment Counsel Inc. now owns 25,842 shares of the medical equipment provider's stock worth $1,839,000 after acquiring an additional 187 shares during the period. Summit Global Investments increased its stake in shares of iRadimed by 2.7% in the 3rd quarter. Summit Global Investments now owns 7,139 shares of the medical equipment provider's stock valued at $508,000 after purchasing an additional 188 shares in the last quarter. CWM LLC increased its stake in shares of iRadimed by 62.2% in the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider's stock valued at $39,000 after purchasing an additional 211 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in iRadimed by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider's stock worth $252,000 after purchasing an additional 234 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 495 shares during the period. Hedge funds and other institutional investors own 92.34% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Lake Street Capital reissued a "buy" rating and issued a $120.00 price objective on shares of iRadimed in a report on Wednesday, February 11th. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of iRadimed in a research note on Monday, December 29th. Finally, Roth Mkm reiterated a "buy" rating and set a $120.00 target price on shares of iRadimed in a research report on Tuesday, February 10th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $120.00.

iRadimed Stock Up 1.4%

IRMD opened at $96.26 on Wednesday. The company has a market cap of $1.23 billion, a PE ratio of 55.01 and a beta of 1.12. iRadimed Corporation has a twelve month low of $47.48 and a twelve month high of $107.90. The company has a 50-day moving average price of $100.09 and a 200 day moving average price of $91.05.

iRadimed (NASDAQ:IRMD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.05. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The company had revenue of $22.69 million for the quarter, compared to analysts' expectations of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, sell-side analysts expect that iRadimed Corporation will post 1.66 earnings per share for the current year.

iRadimed Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were given a dividend of $0.20 per share. The ex-dividend date was Monday, February 23rd. This is a positive change from iRadimed's previous quarterly dividend of $0.17. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. iRadimed's dividend payout ratio (DPR) is presently 45.71%.

Insider Activity at iRadimed

In related news, CEO Roger E. Susi sold 2,500 shares of the stock in a transaction on Tuesday, March 24th. The stock was sold at an average price of $100.28, for a total value of $250,700.00. Following the completion of the transaction, the chief executive officer directly owned 2,232,500 shares of the company's stock, valued at approximately $223,875,100. This represents a 0.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 37,500 shares of company stock worth $3,765,750 in the last three months. 36.80% of the stock is currently owned by insiders.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iRadimed Corporation (NASDAQ:IRMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.